Recursion Pharmaceuticals (RXRX) closed at $4.77 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's 0.47% gain on the day. Meanwhile, the Dow ...

The last time I wrote about Recursion Pharmaceuticals (RXRX), it was with respect to a Seeking Alpha article entitled "Recursion: CDK7 Differentiation Is Initially Paying Off." With respect to this ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

What if machines could not only learn but also teach themselves to become better with each iteration? This isn’t the plot of a sci-fi movie—it’s the reality unfolding in artificial intelligence ...

Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development. For ...

Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025, ...

Add a description, image, and links to the recursive-fibonacci-algorithms topic page so that developers can more easily learn about it.

Katie has a PhD in maths, specializing in the intersection of dynamical systems and number theory. She reports on topics from maths and history to society and animals. Katie has a PhD in maths, ...